Implantable Vascular Device Having Longitudinal Struts
An implantable stent for treating hypertension, the stent having a non-circular cross-section so as to reshape the artery in which the implant is deployed so as to increase strain in the arterial walls to amplify strain signals in the arterial walls by the baroreceptors of the artery. The stent can further include pulsatility enhancing windows of the implantable frame to enhance pulsatility of the vessel wall subsequent implantation.
1 . An implant for treating hypertension in a patient, the implant comprising:
a stent having cells defined by struts such that the stent has a collapsed profile configuration for intravascular delivery to an artery proximate baroreceptors and an expanded configuration in which the struts contact arterial walls of the artery in which the stent is deployed;
wherein the stent in the expanded configuration has a non-circular cross-section so as to reshape the artery in which the implant is deployed so as to increase strain in the arterial walls to amplify strain signals in the arterial walls by the baroreceptors; and
wherein the stent is configured such that a transverse dimension across the stent during diastole is smaller than the transverse dimension during systole, thereby amplifying pulsatility of the arterial walls to enhance a response of the baroreceptors.
2 . The implant of claim 1 , wherein the stent is configured for deployment within the aortic arch.
3 . The implant of claim 1 , wherein the transverse dimension increases by at least 1% in response to systole.
4 . The implant of claim 3 , wherein the increase in the transverse dimension during systole is within a range from about 1% to 7%.
5 . The implant of claim 3 , wherein the increase in the transverse dimension during systole is within a range from about 2% to 4%.
6 . The implant of claim 1 , wherein the stent design includes a plurality of pulsatility enhancing windows.
7 . The implant of claim 6 , wherein the plurality of pulsatility enhancing windows are distributed around the periphery of the stent.
8 . The implant of claim 1 , wherein the stent is formed of metal, and a metal to artery ratio is within a range of about 5-10%.
9 . The implant of claim 8 , wherein the stent is formed of metal, and a metal to artery ratio is within a range of about 5%.
10 . The implant of claim 1 , wherein the stent is formed of Nitinol.
11 . A method of treating hypertension in a patient comprising:
delivering a stent defined by struts in a collapsed profile configuration through vasculature of the patient to an artery of the patient;
deploying the stent to an expanded configuration proximate baroreceptors in the artery so that the struts contact arterial walls of the artery, wherein the stent in the expanded configuration has a non-circular cross-section so as to reshape the artery in which the implant is deployed so as to increase strain in the arterial walls to amplify strain signals in the arterial walls by the baroreceptors; and
amplifying pulsatility of the arterial walls to enhance a response of the baroreceptors by the stent after implantation by virtue of a transverse dimension across the stent during diastole being smaller than the transverse dimension during systole.
12 . The method of claim 11 wherein the stent is deployed within the aortic arch.
13 . The method of claim 11 wherein the transverse dimension increases by at least 1% in response to systole.
14 . The method of claim 13 wherein the increase in the transverse dimension during systole is within a range from about 1% to 7%.
15 . The method of claim 13 wherein the increase in the transverse dimension during systole is within a range from about 2% to 4%.
16 . The method of claim 11 , wherein amplifying pulsatility of the arterial walls further comprise exposing the arterial walls to blood flow through a plurality of pulsatility enhancing windows.
17 . The method of claim 11 , wherein the plurality of pulsatility enhancing windows are distributed around the periphery of the stent.
18 . The method of claim 11 , wherein the stent is formed of metal, and a metal to artery ratio is within a range of about 5-10%.
19 . The method of claim 18 , wherein the stent is formed of metal, and a metal to artery ratio is within a range of about 5%.
20 . The method of claim 11 , wherein the stent is formed of Nitinol.